Premium
Inotilone suppresses phorbol ester‐induced inflammation and tumor promotion in mouse skin
Author(s) -
Kuo YuChing,
Lai ChingShu,
Tsai ChenYu,
Nagabhushanam Kalyanam,
Ho ChiTang,
Pan MinHsiung
Publication year - 2012
Publication title -
molecular nutrition and food research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.495
H-Index - 131
eISSN - 1613-4133
pISSN - 1613-4125
DOI - 10.1002/mnfr.201200073
Subject(s) - dmba , tumor promotion , carcinogenesis , inflammation , cancer research , skin cancer , tumor initiation , pharmacology , medicine , chemistry , cancer , immunology
Scope Chemoprevention is one of the most feasible approaches to reduce the risk of cancer. Over the past decades, scientists have realized that chronic inflammation is a critical component of cancer development. Inotilone, existing in Inonotus mushroom has been reported to exhibit anti‐inflammatory properties in vitro. Hence, we investigated the effects of inotilone on 12‐ O ‐tetradecanoylphorbol‐13‐acetate (TPA)‐mediated acute inflammation and tumor promotion in mouse skin and the underlying molecular mechanisms. Methods and results Inotilone was topically applied to mouse skin 30 min prior to TPA treatment. The results have shown that inotilone inhibited the production of inflammatory mediators by attenuating the activation of nuclear factor‐κB (NF‐κB) and the expression of CCAAT/enhancer binding protein β (C/EBPβ). Furthermore, the ability of inotilone to prevent tumorigenesis at promotion stage was evaluated using a classical two‐stage mouse skin carcinogenesis model. After initiation of 7,12‐dimethylbenz[ a ]anthracene (DMBA), applying inotilone topically before each TPA treatment was found to reduce the tumor incidence and tumor multiplicity of papillomas. Conclusion Based on the results, we concluded that inotilone has potential to be developed into an effective chemopreventive agent for the treatment of a variety of inflammatory diseases, especially the prevention and treatment of epithelial skin cancer.